Table 3.

Active clinical trials investigating combinatorial immunotherapies in mCRC.

Combinatorial Strategy					Stage	Ref.
TLR9 agonist	+	radiosurgery	+	anti-PD1 & anti-CTLA4	Phase I	NCT03507699
STING agonist (MK-1454)			+	anti-PD1	Phase I	NCT03010176
MYB vaccine			+	anti-PD1	Phase I	NCT03287427
KRAS peptide vaccine			+	anti-PD1 & anti-CTLA4	Phase I	NCT04117087
Pexa-Vec oncolytic virus			+	anti-PD1 & anti-CTLA4	Phase I/II	NCT03206073
Oncolytic adenovirus (enadenotucirev)			+	anti-PD-1	Phase I	NCT02636036
Anti-CEA-CD3 bispecific antibody			+	anti-PD1	Phase I	NCT02650713
Anti-GITR			+	anti-PD1 & anti-CTLA4	Phase I/II	NCT03126110
Anti-CD27			+	anti-PD1	Phase I/II	NCT02335918
Anti-HER2 CAR-T cells			+	oncolytic adenovirus	Phase I	NCT03740256
Autologous TIL			+	anti-PD1	Phase II	NCT01174121
Autologous TIL			+	chemotherapy	Phase II	NCT03935893
Anti-PD1 activated autologous TIL			+	chemotherapy	Phase I/II	NCT03904537
Anti-NKG2D CAR-T cells			+	chemotherapy	Phase I	NCT03692429
Anti-CEA CAR-T cells			+	chemotherapy	Phase I/II	NCT02959151
Anti-NKG-2 CAR-T cells			+	chemotherapy	Phase I	NCT03310008
Anti-CEA CAR-T cells			+	internal radiation therapy	Phase I	NCT02416466
TGF-β inhibitor			+	anti-PD1	Phase I/II	NCT03724851
TGF-βRII (extracellular domain; ligand trap)			fused to	anti-PD-L1	Phase I/II	NCT03436563
CCR5 inhibitor			+	anti-PD1	Phase I	NCT03274804 [231]
CCR2/CCR5 inhibitor			+	anti-PD1 or chemotherapy	Phase I/II	NCT03184870
Fluoropyrimidine and bevacizumab			+	anti-PD-L1	Phase III	NCT02291289
CSF-1R inhibitor			+	anti-PD-L1	Phase I	NCT02777710
IDO1 inhibitor + azacytidine			+	anti-PD1	Phase I/II	NCT02959437
K-RAS(G12C) inhibitor			+	anti-PD1	Phase I/II	NCT03600883
Anti-TIM-3 antibody			+	anti-PD-1	Phase I	NCT02817633
Anti-TIM-3 antibody			+	anti-PD-1	Phase I	NCT03099109
Anti-LAG-3			+	anti-PD-1	Phase I/II	NCT01968109
Anti-LAG-3			+	anti-PD-1	Phase I	NCT03250832
Anti-LAG-3			+	anti-PD-1	Phase I	NCT03005782
Anti-LAG-3			+	anti-PD-1	Phase I	NCT03219268